Home/Filings/4/0001209191-13-014352
4//SEC Filing

FEDERICO CHARLES 4

Accession 0001209191-13-014352

CIK 0001138400other

Filed

Mar 4, 7:00 PM ET

Accepted

Mar 5, 7:48 PM ET

Size

27.3 KB

Accession

0001209191-13-014352

Insider Transaction Report

Form 4
Period: 2013-03-01
Transactions
  • Tax Payment

    Common Stock

    2013-03-01$9.07/sh11,977$108,6777,834 total
  • Exercise/Conversion

    Common Stock

    2013-03-01$2.63/sh+20,000$52,60027,834 total
  • Exercise/Conversion

    Stock Options (right to buy)

    2013-03-0120,0000 total
    Exercise: $2.63Exp: 2022-06-11Common Stock (20,000 underlying)
  • Disposition to Issuer

    Stock Options (right to buy)

    2013-03-0110,6530 total
    Exercise: $9.95Exp: 2019-06-18Common Stock (10,653 underlying)
  • Disposition to Issuer

    Stock Options (right to buy)

    2013-03-018,5380 total
    Exercise: $12.66Exp: 2020-06-17Common Stock (8,538 underlying)
  • Exercise/Conversion

    Common Stock

    2013-03-01$5.80/sh+18,736$108,66919,811 total
  • Disposition to Issuer

    Common Stock

    2013-03-0127,8340 total
  • Exercise/Conversion

    Stock Options (right to buy)

    2013-03-0118,7360 total
    Exercise: $5.80Exp: 2021-06-14Common Stock (18,736 underlying)
  • Disposition to Issuer

    Stock Options (right to buy)

    2013-03-0118,0960 total
    Exercise: $17.09Exp: 2017-06-21Common Stock (18,096 underlying)
  • Disposition to Issuer

    Stock Options (right to buy)

    2013-03-018,8400 total
    Exercise: $11.64Exp: 2018-06-19Common Stock (8,840 underlying)
Footnotes (7)
  • [F1]This transaction represents a withholding of shares to cover the payment of exercise price pursuant to an exercise of non-qualified stock options.
  • [F2]Disposed of pursuant to the Agreement and Plan of Merger ("Merger Agreement") dated as of November 19, 2012, by and among the Company, Wright Medical Group, Inc. ("Wright"), Achilles Merger Subsidiary, Inc. and Achilles Acquisition Subsidiary, LLC in exchange for the following merger consideration per share of the Company's common stock: (a) $1.50 in cash, without interest; (b) 0.2482 of a share of Wright's common stock; and (c) one contingent value right ("CVR") issued by Wright.
  • [F3]Option exercised. Pursuant to the Merger Agreement, this stock option was conditionally vested to 100% subject to exercise upon the merger transaction. The reporting person received merger consideration described in footnote (2) above.
  • [F4]Option canceled. Pursuant to the Merger Agreement, the reporting person entered into an agreement with the issuer to terminate stock options with an exercise price greater than $13.00.
  • [F5]Pursuant to the Merger Agreement, the stock options granted by the issuer converted into options to purchase 4,613 shares of Wright common stock at an exercise price of $22.31 per share.
  • [F6]Pursuant to the Merger Agreement, the stock options granted by the issuer converted into options to purchase 5,559 shares of Wright common stock at an exercise price of $19.07 per share.
  • [F7]Pursuant to the Merger Agreement, the stock options granted by the issuer converted into options to purchase 4,455 shares of Wright common stock at an exercise price of $24.26 per share.

Issuer

BIOMIMETIC THERAPEUTICS, INC.

CIK 0001138400

Entity typeother

Related Parties

1
  • filerCIK 0001213215

Filing Metadata

Form type
4
Filed
Mar 4, 7:00 PM ET
Accepted
Mar 5, 7:48 PM ET
Size
27.3 KB